Senner Christopher J.
SEC insider (Form 3/4/5 filer). CIK 0001648367. Director at Quince Therapeutics, Inc. (QNCX) and 1 other issuer. 23 reported Form 4/5 transactions since Sep 2024; latest on Jun 11, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Senner Christopher J. has filed insider reports for
- Quince Therapeutics, Inc. (QNCX): Director
- EXELIXIS, INC. (EXEL): Officer, EVP and CFO
Senner Christopher J.
CIK: 0001648367
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Jun 11, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
2.7K shares- - May 18, 2026EXEL
EXELIXIS, INC.
SaleDirect34.9K shares at avg. $50.00$1.7M - May 15, 2026EXEL
EXELIXIS, INC.
Tax PaymentDirect40.9K shares at avg. $51.10$2.1M - Feb 26, 2026EXEL
EXELIXIS, INC.
AwardDirect52K shares- - Feb 17, 2026EXEL
EXELIXIS, INC.
SaleDirect30.6K shares at avg. $43.67$1.3M - Feb 15, 2026EXEL
EXELIXIS, INC.
Tax PaymentDirect35.9K shares at avg. $43.92$1.6M - Feb 13, 2026EXEL
EXELIXIS, INC.
SaleDirect34.3K shares at avg. $43.00$1.5M - Jan 15, 2026EXEL
EXELIXIS, INC.
AwardDirect149.5K shares- - Jan 15, 2026EXEL
EXELIXIS, INC.
Tax PaymentDirect40.5K shares at avg. $45.23$1.8M - Jan 2, 2026QNCX
Quince Therapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
21.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 2,700 | - | - | Direct |
| May 18, 2026 |  EXEL EXELIXIS, INC. | Sale | 34,901 | $50.00 | $1,745,050 | Direct |
| May 15, 2026 | EXEL EXELIXIS, INC. | Tax Payment | 40,892 | $51.10 | $2,089,581 | Direct |
| Feb 26, 2026 | EXEL EXELIXIS, INC. | Award | 52,018 | - | $0 | Direct |
| Feb 17, 2026 | EXEL EXELIXIS, INC. | Sale | 30,617 | $43.67 | $1,337,044 | Direct |
| Feb 15, 2026 | EXEL EXELIXIS, INC. | Tax Payment | 35,870 | $43.92 | $1,575,410 | Direct |
| Feb 13, 2026 | EXEL EXELIXIS, INC. | Sale | 34,278 | $43.00 | $1,473,954 | Direct |
| Jan 15, 2026 | EXEL EXELIXIS, INC. | Award | 149,474 | - | $0 | Direct |
| Jan 15, 2026 | EXEL EXELIXIS, INC. | Tax Payment | 40,459 | $45.23 | $1,829,961 | Direct |
| Jan 2, 2026 | QNCX Quince Therapeutics, Inc. | Award Director Stock Option (Right to Buy) | 21,810 | - | - | Direct |
1-10 of 23 transactions